Abstract
Objective:
To examine the safety and efficacy of onabotulinumtoxinA (Botox) for plantarflexor overactivity following stroke.
Design:
Double-blind randomized controlled trial, open-label extension phase.
Setting:
Neurology rehabilitation facilities.
Subjects:
Eighty-five subjects with lower limb hypertonia received 200 U (
Primary measures:
Plantarflexor Ashworth scores at 12 weeks post injection and adverse events. Secondary measures: self-reported spasm frequency and pain, physician rating of hypertonia severity, gait quality and active dorsiflexion.
Results:
Differences were not seen between onabotulinumtoxinA groups; hence data were pooled. Incidence of adverse events was not different between groups (
Conclusions:
OnabotulinumtoxinA injection for ankle flexor overactivity after stroke was safe and well tolerated but did not alter local spasticity at 12 weeks; it did reduce spasms and improve gait quality. There were no detectable differences between higher and lower doses. A second injection may be associated with greater change.
Get full access to this article
View all access options for this article.
